Global TCM Granules in Prescriptions Market Strategic Research Report
By Type: Uniform Formula Granules, Compound Formula Granules
By Application: Children, Adults, Elderly
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: Jiangyin Tianjiang(China), Tsumura & Co.(Japan), Tianjin Hongri(China), Sanjiu Medical(China), Sichuan Neo-Green(China), PuraPharm(Hong Kong, China), Jilin Aodong(China), China Shineway Pharmaceutical(China), Anhui Jiren(China), Guangdong Yifang(China), Jiangxi Baishen(China), Heilongjiang Shuanglanxing(China), Zhejiang Jingyuetang(China)
نظرة عامة
Scope of the Report
The global TCM Granules in Prescriptions market size is predicted to grow from US$ 14,903 million in 2025 to US$ 35,055 million in 2032; it is expected to grow at a CAGR of 12.8% from 2026 to 2032.
TCM Granules in Prescriptions refer to standardized granulated formulations produced from single-herb decoction pieces through modern pharmaceutical processes such as extraction, concentration, separation, drying, and granulation. Under the guidance of traditional Chinese medicine (TCM) theory, these granules are prescribed and compounded by physicians and administered through oral dissolution. Combining the therapeutic philosophy of TCM with industrial-level quality control, they offer advantages such as no decoction requirement, precise dosage, portability, and consistent quality, making them a key vehicle for the modernization and standardization of TCM, and a substitute for traditional herbal decoctions.The average gross profit margin of this product is 55%.
Driven by the “Healthy China” strategy and continuous policy support for TCM revitalization, TCM granules are entering a new phase of full market liberalization after the pilot period. The removal of regulatory restrictions and the establishment of unified national standards have significantly expanded market capacity and improved industry standardization. Increasing demand from healthcare institutions for standardized and traceable medicines further accelerates hospital penetration. In addition, aging populations and rising chronic disease prevalence are expanding long-term demand, reinforcing the role of TCM granules in primary care and chronic disease management.With market liberalization, the number of competitors has increased rapidly, breaking previous licensing barriers and intensifying competition under stricter regulatory frameworks. Enhanced national standards for active ingredient content, quality control, and testing systems have raised production costs and compressed margins. Transitional inconsistencies in standard implementation and product registration may lead to short-term supply disruptions. Moreover, volatility in upstream raw material supply and pricing further increases operational uncertainty, potentially reshaping industry concentration.On the demand side, TCM granules are expanding beyond traditional TCM hospitals into general hospitals, primary care institutions, and digital healthcare platforms. Patients’ preference for convenience and standardized treatment is accelerating the substitution of traditional decoctions. Meanwhile, trends toward personalized medicine and chronic disease management are fostering integration with digital healthcare solutions, enabling a shift from product-based to service-oriented models. Growing global acceptance of TCM also opens opportunities for international expansion and export markets.The core raw materials for TCM granules are Chinese medicinal herbs and decoction pieces, whose quality directly determines product efficacy and consistency. Strengthened national standards require higher levels of authenticity, active ingredient control, and traceability, driving upstream cultivation and processing toward standardization and scale. However, herb production remains subject to climate, geographic distribution, and cyclical supply-demand dynamics, resulting in significant price volatility. As a result, supply chain integration, origin-based sourcing, and long-term procurement strategies are becoming critical competitive factors for manufacturers.
This report presents a comprehensive overview of the global TCM Granules in Prescriptions market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Type
- Uniform Formula Granules
- Compound Formula Granules
Segment by Therapeutic Area
- Chronic Diseases
- Respiratory Care
- Digestive System
- Others
Segment by Application
- Hospitals
- Retail Pharmacies
- Other
Segment by Application
- Children
- Adults
- Elderly
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global TCM Granules in Prescriptions market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Children, Adults, Elderly evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global TCM Granules in Prescriptions Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 Uniform Formula Granules
- 3.1.3 Compound Formula Granules
- 3.1.4 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Children
- 4.1.3 Adults
- 4.1.4 Elderly
- 4.1.5 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 Korea
- 6.1.4 Southeast Asia
- 6.1.5 India
- 6.1.6 Australia
- 6.1.7 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 France
- 6.3.3 UK
- 6.3.4 Italy
- 6.3.5 Russia
- 6.3.6 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Egypt
- 6.4.2 South Africa
- 6.4.3 Israel
- 6.4.4 Turkey
- 6.4.5 GCC Countries
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 Jiangyin Tianjiang(China)
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2032)
- 8.2 Tsumura & Co.(Japan)
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2032)
- 8.3 Tianjin Hongri(China)
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2032)
- 8.4 Sanjiu Medical(China)
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2032)
- 8.5 Sichuan Neo-Green(China)
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2032)
- 8.6 PuraPharm(Hong Kong, China)
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2032)
- 8.7 Jilin Aodong(China)
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2032)
- 8.8 China Shineway Pharmaceutical(China)
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2032)
- 8.9 Anhui Jiren(China)
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2032)
- 8.10 Guangdong Yifang(China)
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2032)
- 8.11 Jiangxi Baishen(China)
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2026–2032)
- 8.12 Heilongjiang Shuanglanxing(China)
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2026–2032)
- 8.13 Zhejiang Jingyuetang(China)
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
What is the current global TCM Granules in Prescriptions market size?
What growth rate is expected for the TCM Granules in Prescriptions market through 2032?
How is TCM Granules in Prescriptions defined?
What are the main segments of the TCM Granules in Prescriptions market by type?
Which applications drive demand in the TCM Granules in Prescriptions market?
Who are the key players in the TCM Granules in Prescriptions market?
Which regions and countries are covered for TCM Granules in Prescriptions?
What is driving growth in the TCM Granules in Prescriptions market?
What challenges does the TCM Granules in Prescriptions market face?
Who should buy the TCM Granules in Prescriptions market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global TCM Granules in Prescriptions Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Navadhi Market Research · Pharmaceuticals